Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
World J Gastroenterol. 2024 Mar 21;30(11):1475-1479. doi: 10.3748/wjg.v30.i11.1475.ABSTRACTAcute pancreatitis (AP) is a leading cause of gastrointestinal-related hospitalizations in the United States, resulting in 300000 admissions per year with an estimated cost of over $2.6 billion annually. The severity of AP is determined by the presence of pancreatic complications and end-organ damage. While moderate/severe pancreatitis can be associated with significant morbidity and mortality, the majority of patients have a mild presentation with an uncomplicated course and mortality rate of less than 2%. Despite favorable outcomes...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Darshan J Kothari Sunil G Sheth Source Type: research
Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
World J Gastroenterol. 2024 Mar 21;30(11):1475-1479. doi: 10.3748/wjg.v30.i11.1475.ABSTRACTAcute pancreatitis (AP) is a leading cause of gastrointestinal-related hospitalizations in the United States, resulting in 300000 admissions per year with an estimated cost of over $2.6 billion annually. The severity of AP is determined by the presence of pancreatic complications and end-organ damage. While moderate/severe pancreatitis can be associated with significant morbidity and mortality, the majority of patients have a mild presentation with an uncomplicated course and mortality rate of less than 2%. Despite favorable outcomes...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Darshan J Kothari Sunil G Sheth Source Type: research
Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
World J Gastroenterol. 2024 Mar 21;30(11):1475-1479. doi: 10.3748/wjg.v30.i11.1475.ABSTRACTAcute pancreatitis (AP) is a leading cause of gastrointestinal-related hospitalizations in the United States, resulting in 300000 admissions per year with an estimated cost of over $2.6 billion annually. The severity of AP is determined by the presence of pancreatic complications and end-organ damage. While moderate/severe pancreatitis can be associated with significant morbidity and mortality, the majority of patients have a mild presentation with an uncomplicated course and mortality rate of less than 2%. Despite favorable outcomes...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Darshan J Kothari Sunil G Sheth Source Type: research
Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
World J Gastroenterol. 2024 Mar 21;30(11):1475-1479. doi: 10.3748/wjg.v30.i11.1475.ABSTRACTAcute pancreatitis (AP) is a leading cause of gastrointestinal-related hospitalizations in the United States, resulting in 300000 admissions per year with an estimated cost of over $2.6 billion annually. The severity of AP is determined by the presence of pancreatic complications and end-organ damage. While moderate/severe pancreatitis can be associated with significant morbidity and mortality, the majority of patients have a mild presentation with an uncomplicated course and mortality rate of less than 2%. Despite favorable outcomes...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Darshan J Kothari Sunil G Sheth Source Type: research
Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
ConclusionsThis real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder
Conclusions: This study found that AEs occurring during ADHD treatment episodes are associated with significant healthcare costs. This highlights the potential of treatments with favorable safety profiles to alleviate the burden experienced by patients and the healthcare system.PMID:38602691 | DOI:10.1080/13696998.2024.2342749 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 11, 2024 Category: Health Management Authors: Jeff Schein Martin Cloutier Rebecca Bungay Marjolaine Gauthier-Loiselle Ann Childress Source Type: research
Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence
Conclusion: The use of MCOT versus ILR as the primary monitor following IS was associated with significant decreases in readmission, lower costs for the initial IS and total care over the next 18 months, significantly lower mortality for patients with complications and comorbidities at the index stroke, and a trend toward improved survival across all patients.PMID:38602503 | DOI:10.57264/cer-2024-0008 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 11, 2024 Category: General Medicine Authors: Vincent Norlock Reynaldo Vazquez Alexandria Dunn Christian Siegfried Manish Wadhwa Goran Medic Source Type: research
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder
Conclusions: This study found that AEs occurring during ADHD treatment episodes are associated with significant healthcare costs. This highlights the potential of treatments with favorable safety profiles to alleviate the burden experienced by patients and the healthcare system.PMID:38602691 | DOI:10.1080/13696998.2024.2342749 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 11, 2024 Category: Health Management Authors: Jeff Schein Martin Cloutier Rebecca Bungay Marjolaine Gauthier-Loiselle Ann Childress Source Type: research
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China
CONCLUSIONS: Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.CLINICAL TRIAL REGISTRATION: ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.PMID:38594905 | DOI:10.1080/14737167.2024.2341859 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 10, 2024 Category: Health Management Authors: Wei Li Li Wan Source Type: research
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China
CONCLUSIONS: Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.CLINICAL TRIAL REGISTRATION: ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.PMID:38594905 | DOI:10.1080/14737167.2024.2341859 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 10, 2024 Category: Health Management Authors: Wei Li Li Wan Source Type: research
